Cardiovascular and interventional radiology · 2025
Comparison of Drug-Coated Balloon versus Plain Balloon Angioplasty for the Treatment of Arteriovenous Fistula Stenosis: A systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Zhi-Wei, Li Han-Bo, Yang Xue-Song, Qin Hong-Song, Hao Qing-Zhi
Аннотация
PURPOSE: Drug-coated balloon (DCB) angioplasty is a promising therapy for arteriovenous fistula (AVF) stenosis in hemodialysis patients. However, comparative evidence on the long-term efficacy of DCB versus plain balloon angioplasty (PBA), the sources of heterogeneity, and its differential effects on various access types remains inconclusive. This meta-analysis synthesizes randomized controlled trial (RCT) data to evaluate clinical outcomes of these approaches.
MATERIALS: This meta-analysis of randomized controlled trials (RCTs) evaluated DCB versus PBA for AVF stenosis (PROSPERO CRD420250651907). We systematically searched PubMed, Embase, and Web of Science from inception to February 17, 2025, for RCTs reporting 6-month target lesion primary patency.
RESULTS: Twenty-one RCTs (n = 2,537 patients) were included. DCB significantly improved primary patency at 6 months (OR 2.43, 95% CI: 1.81-3.27; P = 0.002) and 12 months (OR 1.88, 95% CI: 1.54-2.30; P = 0.230), but the benefit attenuated at 24 months (OR 1.36, 95% CI: 1.00-1.85; P = 0.794). Complication and mortality rates were comparable between groups at all timepoints.
CONCLUSIONS: DCB angioplasty provides superior short-to-medium-term primary patency versus PBA for AVF stenosis, although this benefit diminishes with prolonged follow-up. The two modalities show comparable safety. The higher initial cost of DCB necessitates individualized treatment decisions based on patient life expectancy and lesion characteristics.
MATERIALS: This meta-analysis of randomized controlled trials (RCTs) evaluated DCB versus PBA for AVF stenosis (PROSPERO CRD420250651907). We systematically searched PubMed, Embase, and Web of Science from inception to February 17, 2025, for RCTs reporting 6-month target lesion primary patency.
RESULTS: Twenty-one RCTs (n = 2,537 patients) were included. DCB significantly improved primary patency at 6 months (OR 2.43, 95% CI: 1.81-3.27; P = 0.002) and 12 months (OR 1.88, 95% CI: 1.54-2.30; P = 0.230), but the benefit attenuated at 24 months (OR 1.36, 95% CI: 1.00-1.85; P = 0.794). Complication and mortality rates were comparable between groups at all timepoints.
CONCLUSIONS: DCB angioplasty provides superior short-to-medium-term primary patency versus PBA for AVF stenosis, although this benefit diminishes with prolonged follow-up. The two modalities show comparable safety. The higher initial cost of DCB necessitates individualized treatment decisions based on patient life expectancy and lesion characteristics.